Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingke Pingchuan Granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by Jiangsu Shengze Hospital (Affiliated Shengze Hospital of Nanjing Medical University) for the treatment of community-acquired pneumonia (CAP). It is specifically indicated for patients presenting with the 'phlegm-heat obstructing lung' syndrome, a common TCM pattern in respiratory infections characterized by cough, fever, and dyspnea. The formulation is designed to clear pulmonary heat, resolve phlegm, and alleviate wheezing. Clinical observations suggest that the granule, when used as an adjunctive therapy, can reduce systemic inflammatory markers such as C-reactive protein (CRP), Interleukin-6 (IL-6), and Tumor Necrosis Factor-alpha (TNF-α), thereby improving clinical recovery rates and accelerating the resolution of pulmonary inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingke Pingchuan Granule.